Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

Mycosis fungoides (MF) and Sézary syndrome (SS) are common subtypes of cutaneous T‐cell lymphoma that primarily affect the skin but may spread to the lymph nodes, viscera and blood. The symptom burden may compromise health‐related quality of life (HRQL). The phase 3 MAVORIC study (ClinicalTrials.gov identifier NCT01728805) in patients with relapsed/refractory MF/SS reported improved HRQL with mogamulizumab compared with vorinostat.

• Publication year

  2024

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2024-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jdv.20357PMID 39315857PMCID 11934017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

  2024cited by this paper
• Gender disparities in health-related quality of life (HRQoL) in patients with cutaneous T-cell lymphoma

  2023cited by this paper
• EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)

  2022cited by this paper
• The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas

  2021cited by this paper
• EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: real-world data in Spanish patients (MICADOS study).

  2021influential reference
• Health-related quality of life effect of mogamulizumab by patient blood involvement.

  2021cited by this paper
• Health‐related quality of life in cutaneous T‐cell lymphoma: A cross‐sectional survey study

  2021influential reference
• Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.

  2020cited by this paper
• Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study

  2020cited by this paper
• Gender differences in health-related quality of life among patients with colorectal cancer.

  2019cited by this paper
• Itching for the right treatment

  2019cited by this paper
• Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

  2019cited by this paper
• The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

  2019cited by this paper
• Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

  2018cited by this paper
• Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial.

  2018cited by this paper
• Evaluation of Symptom and Side Effect Bother in Cutaneous T-cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat

  2018cited by this paper
• Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument

  2018cited by this paper
• An overview of cutaneous T cell lymphomas

  2016cited by this paper
• ItchyQoL bands: pilot clinical interpretation of scores.

  2015cited by this paper
• Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy

  2014cited by this paper
• Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

  2014cited by this paper
• Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma.

  2013cited by this paper
• The Skindex instruments to measure the effects of skin disease on quality of life.

  2012cited by this paper
• Interpretation of Skindex-29 scores: response to Sampogna and Abeni.

  2012cited by this paper
• Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.

  2012cited by this paper
• Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population

  2012cited by this paper
• Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life.

  2011cited by this paper
• Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.

  2010cited by this paper
• Quality of life and psychological distress in patients with cutaneous lymphoma

  2009cited by this paper
• A pilot quality-of-life instrument for pruritus.

  2008cited by this paper
• Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.

  2008cited by this paper
• Significant impact of cutaneous T‐cell lymphoma on patients' quality of life

  2006cited by this paper
• Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma.

  2005cited by this paper
• Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population.

  2001cited by this paper
• Regression Shrinkage and Selection via the Lasso

  1996cited by this paper

• Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.

  2025cites this paper
• Pruritus Is an Indicator for Quality of Life in Cutaneous T‐Cell Lymphoma

  2025cites this paper
• Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

  2024cites this paper
• Evaluation of Psychological Symptoms and Quality of Life in Patients with Early-Stage Mycosis Fungoides: A Case-Control Study

  2024cites this paper